Development of multi-route physiologically-based pharmacokinetic models for ethanol in the adult, pregnant, and neonatal rat

被引:16
作者
Martin, Sheppard A. [1 ]
McLanahan, Eva D. [2 ]
El-Masri, Hisham [3 ]
LeFew, William R. [3 ]
Bushnell, Philip J. [1 ]
Boyes, William K. [1 ]
Choi, Kyoungju [4 ]
Clewell, Harvey J., III [4 ]
Campbell, Jerry L., Jr. [4 ]
机构
[1] US EPA, NB, TAD, NHEERL,ORD, Res Triangle Pk, NC 27711 USA
[2] NCEA, ORD, Res Triangle Pk, NC USA
[3] ISTD, SBB, ORD, Res Triangle Pk, NC USA
[4] Hamner Inst Hlth Sci, Res Triangle Pk, NC USA
关键词
Ethanol; Pharmacokinetics; PBPK model; Multi-route; Life-stage; FETAL ALCOHOL SYNDROME; CEREBELLAR PURKINJE-CELLS; APOPTOTIC NEURODEGENERATION; GASTROINTESTINAL TRANSIT; DEHYDROGENASE ACTIVITY; SYNAPTIC PLASTICITY; COGNITIVE FUNCTION; OXIDIZING SYSTEM; DEVELOPING BRAIN; ANIMAL-MODEL;
D O I
10.3109/08958378.2012.712165
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Biofuel blends of 10% ethanol (EtOH) and gasoline are common in the USA, and higher EtOH concentrations are being considered (15-85%). Currently, no physiologically-based pharmacokinetic (PBPK) models are available to describe the kinetics of EtOH-based biofuels. PBPK models were developed to describe life-stage differences in the kinetics of EtOH alone in adult, pregnant, and neonatal rats for inhalation, oral, and intravenous routes of exposure, using data available in the open literature. Whereas ample data exist from gavage and intravenous routes of exposure, kinetic data from inhalation exposures are limited, particularly at concentrations producing blood and target tissue concentrations associated with developmental neurotoxicity. Compared to available data, the three models reported in this paper accurately predicted the kinetics of EtOH, including the absorption, peak concentration, and clearance across multiple datasets. In general, model predictions for adult and pregnant animals matched inhalation and intravenous datasets better than gavage data. The adult model was initially better able to predict the time-course of blood concentrations than was the neonatal model. However, after accounting for age-related changes in gastric uptake using the calibrated neonate model, simulations consistently reproduced the early kinetic behavior in blood. This work provides comprehensive multi-route life-stage models of EtOH pharmacokinetics and represents a first step in development of models for use with gasoline-EtOH blends, with additional potential applicability in investigation of the pharmacokinetics of EtOH abuse, addiction, and toxicity.
引用
收藏
页码:698 / 722
页数:25
相关论文
共 50 条
  • [31] A Novel Method for Assessing Drug Degradation Product Safety Using Physiologically-Based Pharmacokinetic Models and Stochastic Risk Assessment
    Nguyen, Hoa Q.
    Stamatis, Stephen D.
    Kirsch, Lee E.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (09) : 3101 - 3119
  • [32] Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies
    Atoyebi, Shakir Adeyinka
    Rajoli, Rajith K. R.
    Adejuyigbe, Ebunoluwa
    Owen, Andrew
    Bolaji, Oluseye
    Siccardi, Marco
    Olagunju, Adeniyi
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 140
  • [33] Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model
    Loccisano, Anne E.
    Campbell, Jerry L., Jr.
    Butenhoff, John L.
    Andersen, Melvin E.
    Clewell, Harvey J., III
    REPRODUCTIVE TOXICOLOGY, 2012, 33 (04) : 452 - 467
  • [34] Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach
    Yoshii, Kazuyoshi
    Iikura, Minami
    Hirayama, Masamichi
    Toda, Ryoko
    Kawabata, Yoshihiro
    PHARMACEUTICAL RESEARCH, 2016, 33 (02) : 292 - 300
  • [35] Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients
    McPhail, Brooks T.
    Emoto, Chie
    Fukuda, Tsuyoshi
    Butler, Dawn
    Wiles, Jason R.
    Akinbi, Henry
    Vinks, Alexander A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (04) : 453 - 465
  • [36] Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach
    Kazuyoshi Yoshii
    Minami Iikura
    Masamichi Hirayama
    Ryoko Toda
    Yoshihiro Kawabata
    Pharmaceutical Research, 2016, 33 : 292 - 300
  • [37] Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations
    Sanchez Restrepo, Frank
    Hernandez Valdivieso, Alher Mauricio
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2022, 49 (04) : 411 - 428
  • [38] Evaluation of Age-Related Pyrethroid Pharmacokinetic Differences in Rats: Physiologically-Based Pharmacokinetic Model Development Using In Vitro Data and In Vitro to In Vivo Extrapolation
    Song, Gina
    Moreau, Marjory
    Efremenko, Alina
    Lake, Brian G.
    Wu, Huali
    Bruckner, James V.
    White, Catherine A.
    Osimitz, Thomas G.
    Creek, Moire R.
    Hinderliter, Paul M.
    Clewell, Harvey J.
    Yoon, Miyoung
    TOXICOLOGICAL SCIENCES, 2019, 169 (02) : 365 - 379
  • [39] Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice
    Hsuan-Ping Chang
    Zhe Li
    Dhaval K. Shah
    Pharmaceutical Research, 2022, 39 : 1 - 24
  • [40] Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice
    Chang, Hsuan-Ping
    Li, Zhe
    Shah, Dhaval K.
    PHARMACEUTICAL RESEARCH, 2022, 39 (01) : 1 - 24